These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19266613)

  • 1. Lubiprostone: clinical applications beyond constipation.
    Kapoor S
    World J Gastroenterol; 2009 Mar; 15(9):1147. PubMed ID: 19266613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series.
    O'Brien CE; Anderson PJ; Stowe CD
    Ann Pharmacother; 2010 Mar; 44(3):577-81. PubMed ID: 20179256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.
    MacDonald KD; McKenzie KR; Henderson MJ; Hawkins CE; Vij N; Zeitlin PL
    Am J Physiol Lung Cell Mol Physiol; 2008 Nov; 295(5):L933-40. PubMed ID: 18805957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia.
    Schiffhauer ES; Vij N; Kovbasnjuk O; Kang PW; Walker D; Lee S; Zeitlin PL
    Am J Physiol Lung Cell Mol Physiol; 2013 Mar; 304(5):L324-31. PubMed ID: 23316067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.
    De Lisle RC; Mueller R; Roach E
    BMC Gastroenterol; 2010 Sep; 10():107. PubMed ID: 20843337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator.
    Bijvelds MJ; Bot AG; Escher JC; De Jonge HR
    Gastroenterology; 2009 Sep; 137(3):976-85. PubMed ID: 19454284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility.
    Jakab RL; Collaco AM; Ameen NA
    Dig Dis Sci; 2012 Nov; 57(11):2826-45. PubMed ID: 22923315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enteric nervous system: sensory physiology, diarrhea and constipation.
    Wood JD
    Curr Opin Gastroenterol; 2010 Mar; 26(2):102-8. PubMed ID: 19926984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study.
    O'Brien CE; Anderson PJ; Stowe CD
    Ann Pharmacother; 2011 Sep; 45(9):1061-6. PubMed ID: 21852592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lubiprostone: a chloride channel activator.
    Lacy BE; Levy LC
    J Clin Gastroenterol; 2007 Apr; 41(4):345-51. PubMed ID: 17413599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lubiprostone: a novel treatment for chronic constipation.
    Lacy BE; Levy LC
    Clin Interv Aging; 2008; 3(2):357-64. PubMed ID: 18686757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lubiprostone: a new drug for the treatment of chronic idiopathic constipation.
    Baker DE
    Rev Gastroenterol Disord; 2007; 7(4):214-22. PubMed ID: 18192957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lubiprostone: chloride channel activator for chronic constipation.
    Rivkin A; Chagan L
    Clin Ther; 2006 Dec; 28(12):2008-21. PubMed ID: 17296458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lubiprostone for the treatment of opioid-induced bowel dysfunction.
    Wong BS; Camilleri M
    Expert Opin Pharmacother; 2011 Apr; 12(6):983-90. PubMed ID: 21385112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lubiprostone targets prostanoid EP₄ receptors in ovine airways.
    Cuthbert AW
    Br J Pharmacol; 2011 Jan; 162(2):508-20. PubMed ID: 20883477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
    Chamberlain SM; Rao SS
    Expert Opin Drug Saf; 2012 Sep; 11(5):841-50. PubMed ID: 22834474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
    Schey R; Rao SS
    Dig Dis Sci; 2011 Jun; 56(6):1619-25. PubMed ID: 21523369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chloride transporting capability of Calu-3 epithelia following persistent knockdown of the cystic fibrosis transmembrane conductance regulator, CFTR.
    MacVinish LJ; Cope G; Ropenga A; Cuthbert AW
    Br J Pharmacol; 2007 Apr; 150(8):1055-65. PubMed ID: 17339840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors.
    Hayashi S; Kurata N; Yamaguchi A; Amagase K; Takeuchi K
    J Pharmacol Exp Ther; 2014 Jun; 349(3):470-9. PubMed ID: 24713141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders.
    Ginzburg R; Ambizas EM
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1091-7. PubMed ID: 18680443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.